de Leeuw P W
Department of Medicine, University Hospital Maastricht, The Netherlands.
Am J Hypertens. 1995 Oct;8(10 Pt 2):68S-70S. doi: 10.1016/0895-7061(95)00192-1.
Trandolapril is a new angiotensin converting enzyme (ACE) inhibitor that effectively lowers blood pressure in doses up to 2 mg. Only a small additional effect is seen with higher doses. The drug is transformed in vivo to the active metabolite trandolaprilat. When renal function is severely impaired a dose reduction may be necessary because the clearance of trandolaprilat is significantly correlated to creatinine clearance. Trandolapril has a sustained action that is reflected in long-lasting inhibition of ACE, even after discontinuation of treatment. Blood pressure is controlled by the drug in about 60% of patients with a side effect profile that is comparable to that of the other ACE inhibitors. Trandolapril can be given safely over a prolonged period of time.
群多普利是一种新型血管紧张素转换酶（ACE）抑制剂，剂量高达2毫克时可有效降低血压。更高剂量时仅见微小的附加效应。该药物在体内转化为活性代谢产物群多普利拉。当肾功能严重受损时，可能需要减少剂量，因为群多普利拉的清除率与肌酐清除率显著相关。群多普利具有持续作用，即使在停药后，也能长期抑制ACE。约60%的患者血压可由该药物控制，其副作用与其他ACE抑制剂相当。群多普利可长期安全给药。
